Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...
Gemma Roberts, national influencing manager for Alzheimer's Society in Wales, said: "Disease-modifying treatments like donanemab and lecanemab offer a new horizon of hope in the fight against dementia ...
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
England's drug-cost regulator rejcted Eli Lilly's Alzheimer's drug for use in the country's public health system, marking the second time a treatment for the disease has been deemed too costly.
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...